ArticleCardiovascular and interventional radiology2025
Outcomes of Post-transplant Percutaneous Portal Vein Interventions: A Single Pediatric Liver Transplantation Center Experience.
Article in Cardiovascular and interventional radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the long-term results of transhepatic treatment of portal vein complications (PVCs) after pediatric liver transplantation (PLTx) at a single center. MATERIALS AND
methodsAll interventional procedures for PVCs after PLTx performed between 2005 and 2023 were retrospectively analyzed. Clinical signs of portal hypertension and portal vein (PV) flow velocity on Doppler ultrasound were routinely assessed during follow-up. Primary patency, assisted primary patency, and survival rates were evaluated.
resultsOut of 275 consecutive PLTs, 26 children (median age 19.8 months, range: 8.5-154.1) underwent 39 endovascular procedures for PVCs. Technical success was achieved in 97% of procedures. The median time interval between PLTx and the procedure was 5.4 months (range: 0.27-57.1). Percutaneous transluminal angioplasty (PTA) was performed in 81%, stenting in 15%, and thrombolysis in 4% of cases as the primary intervention. A significant decrease in the median trans-stenotic pressure gradient from 9 mmHg (range 4-22) to 1 mmHg (range 0-10) (p < 0.001) was observed. Recurrent stenosis was observed in 31% of patients. Two procedural complications occurred, both managed conservatively. Primary patency rates at 6 months, 1, 3, 5, and 10 years were 74%, 68%, 65%, 54%, 54%, respectively. Assisted primary patency remained 100%. The patient survival rate was 96% at all intervals. The median follow-up time was 60.47 months (range 2.2-174.3).
conclusionPTA should be the preferred first-line treatment for PV stenosis in PLTx recipients, with stenting reserved for refractory cases. PTA is applicable for selected cases of PV thrombosis. Regular surveillance and timely interventions ensure favorable long-term outcomes.
Indexed as
Identifiers
40524033What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.